CIK 0001815776 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
LENZ Therapeutics, Inc.
Sign in to watch- Ticker
- LENZ
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 844867570
- Phone
- 858-925-7000
- Business address
- 201 LOMAS SANTA FE DRIVE, SUITE 300, SOLANA BEACH, CA, 92075
- Former names
- Graphite Bio, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $9,134,778
- in 1 filing
Net −$9,134,778. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-10-30 | Chevallard Daniel R. Chief Financial Officer | Grant or award · Stock Option (right to buy) | +652,063 | 652,063 | ||
| 2026-10-29 | RA CAPITAL MANAGEMENT, L.P. 10% owner | Sale | −2,159,516 | $3.36 | $7.3M | 1,159,823 |
| 2026-10-29 | RA CAPITAL MANAGEMENT, L.P. 10% owner | Sale | −451,998 | $3.36 | $1.5M | 242,757 |
| 2026-10-29 | RA CAPITAL MANAGEMENT, L.P. 10% owner | Sale | −107,170 | $3.36 | $360K | 57,559 |
| 2026-06-15 | Guerard Frederic Director | Grant or award · Stock Option (right to buy) | +22,100 | 22,100 | ||
| 2026-06-15 | Scheiner Zachary Director | Grant or award · Stock Option (right to buy) | +22,100 | 22,100 | ||
| 2026-06-15 | George Jeffrey P. Director | Grant or award · Stock Option (right to buy) | +22,100 | 22,100 | ||
| 2026-06-15 | Drapkin Kimberlee C Director | Grant or award · Stock Option (right to buy) | +22,100 | 22,100 | ||
| 2026-06-15 | Thunen Shelley B Director | Grant or award · Stock Option (right to buy) | +22,100 | 22,100 | ||
| 2026-06-15 | RA CAPITAL MANAGEMENT, L.P. Director | Grant or award · Stock Option (right to buy) | +22,100 | 22,100 | ||
| 2026-06-15 | MCCOLLUM JAMES W Director | Grant or award · Stock Option (right to buy) | +22,100 | 22,100 | ||
| 2026-03-27 | George Jeffrey P. Director | Purchase | +5,592 | $8.92 | $50K | 5,592 |
| 2026-03-27 | Schimmelpennink Evert B. President, CEO and Secretary | Purchase | +28,089 | $8.95 | $251K | 77,289 |
| 2026-03-27 | Chevallard Daniel R. Chief Financial Officer | Purchase | +7,500 | $8.57 | $64K | 12,886 |
| 2026-01-02 | Odrich Marc Chief Medical Officer | Grant or award · Stock Option (right to buy) | +84,200 | 84,200 | ||
| 2026-01-02 | Odrich Marc Chief Medical Officer | Grant or award · Restricted Stock Unit | +14,000 | 14,000 | ||
| 2026-01-02 | Olsson Shawn Chief Commercial Officer | Grant or award · Stock Option (right to buy) | +84,200 | 84,200 | ||
| 2026-01-02 | Olsson Shawn Chief Commercial Officer | Grant or award · Restricted Stock Unit | +14,000 | 14,000 | ||
| 2026-01-02 | Schimmelpennink Evert B. President, CEO and Secretary | Grant or award · Stock Option (right to buy) | +358,100 | 358,100 | ||
| 2026-01-02 | Chevallard Daniel R. Chief Financial Officer | Grant or award · Stock Option (right to buy) | +84,200 | 84,200 |
Page 1 of 11 · 217 trades